硼替佐米联合地塞米松治疗初发的多发性骨髓瘤的疗效评价.pdf

浙江大学硕士学位论文 总体反应率为100％。MP方案治疗初发的多发性骨髓瘤的总反应率为66．7％。 M2方案的总反应率为76．9％。VAD方案的总反应率为89．6％。硼替佐米组疗效 优于传统化疗组。 结论： 硼替佐米治疗初发多发性骨髓瘤的临床疗效显著，不良反应相对轻微，尤其 在高龄患者中具有优势。 关键词： 硼替佐米多发性骨髓瘤 2 浙江大学硕士学位论文 Treatmentof NewlyDiagnosed MultipleMyeloma BasedonBortezomibDexamethasone plus MedicalSchool University ofZhejiang CandidatemasterofmedicineJin Huan如ng ProfessorCaiZhen Supervisor objective a is diseasethatischaracterizedclonal MuItipIemyeloma by proliferation to still to柚uncumbledisease．ItWasconfirmed ofplasma now，it cells．Up equals that New in activethetreatment Bortezom／b，aantineoplas缸drug,is ofmultiple ithasachieved ratein or myeloma,and encollragingresponserelapsedrefractory weevaluatetheclinical ofbortezomib multiplemyeloma．Therefore efficacy plus dexamethasonefor untreatedwitlI previouslypatientsmuhiplemyeloma． Methods Eightnewlydiagnosedpatients、Ⅳitllmultiple 4-female4 myeloma(male median was61 45-73 treated eases)，whose age yearsold(rangeyearseld)，were with bortezomib theFirstaffiliated of plusdexamethasone,in hospitalZheJiang the of2006～2007．Other48 19 Universityduringyear 29，f